Fecal Microbiota Transplantation for Irritable Bowel Syndrome
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT03613545, who can take part
Where in China
- Guangzhou First People's HospitalGuangzhou, ChinaContact: Hongli Huang, MMTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Guangzhou First People's Hospital
- Trial code
- NCT03613545
- Record updated
- 3 August 2021
- Original description
Fecal microbiota transplantation (FMT) is a strategy that infuses a fecal suspension containing a healthy donor's microbiota into a patient's gut to restore his/her intestinal microbiome. FMT has a higher cure rate than standard antibiotic treatment for recurrent Clostridium difficile infections,and shows promising results in Inflammatory bowel disease（IBD）.However, few studies have evaluated whether FMT is effective to treat Irritable bowel syndrome(IBS).The investigators propose to determine the efficiency and safety of FMT in patients with Irritable bowel syndrome.Read full original descriptionShow less
Efficacy and Safety of Fecal Microbiota Transplantation for Irritable Bowel Syndrome
Fecal microbiota transplantation (FMT) is a strategy that infuses a fecal suspension containing a healthy donor's microbiota into a patient's gut to restore his/her intestinal microbiome. FMT has a higher cure rate than standard antibiotic treatment for recurrent Clostridium difficile infections,and shows promising results in Inflammatory bowel disease（IBD）.However, few studies have evaluated whether FMT is effective to treat Irritable bowel syndrome(IBS).The investigators propose to determine the efficiency and safety of FMT in patients with Irritable bowel syndrome.
Inclusion: To be considered eligible for enrolment into the study, subjects must:; Be able to give written informed consent; Males and females aged >18 and <75; Have IBS as defined by the Rome IV criteria.
Exclusion: suffering from other severe disease ,including liver and kidney failure, cancers, intestinal diseases, inflammatory bowel disease, C difficile infection; Subjects will be excluded from the study if they meet any of the below criteria:; pregnant or having a follow-up of less than 6 months; unable to give informed consent; unable to undergo endoscopy.